London Stock Exchange welcomes Genflow Biosciences Plc to the Main Market

London Stock Exchange today welcomes Genflow Biosciences Plc, a UK-based biotechnology company focused on longevity and the development of therapies to counteract the effects of aging and diseases associated with advanced age, to the Standard Listing Segment of the Main Market, under the ticker symbol "GENF".

Genflow Biosciences opened the markets of the London Stock Exchange to mark the occasion of its historic Initial Public Offering as the first pure-play longevity biotechnology firm to list in Europe. Genflow’s listing comes at a time when the fast-growing longevity sector is increasingly becoming the focus of significant clinical research and is attracting considerable global capital.

The past 15 years have seen extraordinary developments in the understanding of the biology of ageing, on which the scientific and biotechnology community can now act. In light of this increased understanding, Genflow's Directors believe that ageing is a multifactorial, complex biological process which can be influenced through innovative gene therapies to achieve healthier longevity.

Genflow is currently undertaking pre-clinical trials which are expected to take approximately two years. The Company is developing gene therapies designed to target the ageing process and to reduce and delay the incidence of age-related diseases. This will be done through novel therapeutics targeting ageing in humans and dogs.

Genflow Biosciences has raised gross proceeds of £3.7m in an oversubscribed placing and upon admission, the Company will have a market capitalisation of approximately £23.4 million at the Placing Price.

Proceeds from the share placing will be deployed to further the Company’s research into the impact of the Sirtuin-6 ("SIRT6") gene variant on the ageing process and its potential beneficial impact on health spans. SIRT6 is a gene mutation found in centenarians that has already been shown to have significant capabilities to repair DNA damage and has yielded promising pre-clinical results.

Quick facts

Market: Main Market
Instrument market cap (£m)
Listing/Admission to trading
17 Jan 2022

Dr. Eric Leire, Founder and CEO of Genflow Biosciences, said:

"The successful placing and admission of our shares to trading on the Main Market are major milestones for Genflow Biosciences. The funds raised will be used to further our development of life-changing gene therapies to target the ageing process and to develop our lead compound, GF-1002, a recombinant AAV containing a transgene encoding the cDNA (coding DNA) portion of a variant of the human SIRT6 gene found in centenarians.

“The strong support we have received from investors in our oversubscribed placing demonstrates the revenue potential and attractiveness of the investment proposition that Genflow offers the market, and we would like to thank our new and existing investors for joining us on this exciting journey.

“We have confidence that Genflow Biosciences can both generate value for investors and make a real difference in people's lives.”

The Company was advised by Clear Capital Markets Ltd, acting as broker; Westend Corporate LLP acting as company secretary and corporate adviser; PKF Littlejohn LLP, acting as auditors and reporting accountants; Hill Dickinson LLP, acting as legal advisers; and Tancredi Intelligent Communication Ltd, acting as financial public relations.

Looking for new and recent issues?

More recent

London Stock Exchange Group welcomes The Future Investment Initiative Institute, celebrating the launch of the FII regional summit “Inclusive ESG for Emerging Markets”

The Future Investment Initiative (FII) Institute is a new global nonprofit foundation with an investment arm and one agenda: Impact on Humanity. Global, inclusive and committed to ESG principles, the FII Institute fosters great minds from around the world and turn ideas into real-world solutions in four critical areas: AI and Robotics, Education, Healthcare and Sustainability. The FII Institute

Learn more
European Assets Trust PLC celebrates 50 years.

This year, European Assets Trust PLC celebrates its fiftieth anniversary since launch in May 1972. The Company was created in 1972 following the acquisition of a Dutch investment company ‘Mijbeb NV’ by a consortium of United Kingdom institutional investors and the appointment of a predecessor of BMO Investment Business Limited as its Manager.

Initially the Company was listed solely on

Learn more
London Stock Exchange welcomes Grayscale and HANetf Celebrating the launch of Grayscale Future of Finance UCITS ETF

Grayscale Investments®, the world’s largest digital currency asset manager, today announced its first European ETF, Grayscale Future of Finance UCITS ETF (ticker: GFOF), that has listed on the London Stock Exchange (LSE) and will also be passported for sale across Europe.  

GFOF tracks the investment performance of the Bloomberg Grayscale Future of Finance Index and seeks to offe

Learn more
London Stock Exchange Group welcomes His Worship The Mayor of Islington, Cllr Troy Gallagher, and his chosen charities

His Worship The Mayor of Islington, Cllr Troy Gallagher opened the market in celebration of his year in office. Throughout the year, the Mayor has supported three chosen charities - ICAP, forum+ and James Place – helping to raise funds and build awareness of their work. Cllr Gallagher is the first Mayor of Islington from the Republic of Ireland and has represented the Bunhill ward as a councill

Learn more